Sino BiopharmaceuticalSBMFF -4.96%62 Gross Margin % is 81.58% as of Dec. 2025, which is 2% above its 10-year median of 80.03. GuruFocus rates SBMFF with a GF Score™ of 62/100 and a GF Value™ of $0.67 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 736 Biotechnology companies, Sino Biopharmaceutical ranks better than 74.46% on this metric.
SBMFF's Gross Margin % is ranked better than 74.46% of 736
companies
in the Biotechnology industry
Industry Median: 60.91
vs SBMFF: 82.07
Sino Biopharmaceutical had a gross margin of 81.58% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Sino Biopharmaceutical was 0.80% per year.
Sino Biopharmaceutical (OTCPK:SBMFF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sino Biopharmaceutical had a gross margin of 81.58% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Sino Biopharmaceutical Gross Margin % Related Terms
Sino Biopharmaceutical Gross Margin % Historical Data
* Premium members only.
The historical data trend for Sino Biopharmaceutical's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBMFF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sino Biopharmaceutical (SBMFF) has a Gross Margin % of 81.58% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Sino Biopharmaceutical and its competitors. This is near median its historical median of 80.03. Over the past decade, Sino Biopharmaceutical's Gross Margin % has ranged from 78.08 to 82.76. According to the industry distribution chart, Sino Biopharmaceutical ranks #188 out of 736 companies in the Biotechnology industry, placing it in the top 25.5%.
Is Sino Biopharmaceutical's Gross Margin % too high?
Sino Biopharmaceutical's current Gross Margin % of 81.58% is near median its 10-year median of 80.03. Over the past 10 years, this metric has ranged from a low of 78.08 to a high of 82.76. The Biotechnology industry median Gross Margin % is 60.91. Sino Biopharmaceutical's value of 81.58% is 33.9% above this industry median. Based on the distribution chart, Sino Biopharmaceutical ranks #188 out of 736 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sino Biopharmaceutical has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #188 out of 736 companies for Gross Margin %. This puts Sino Biopharmaceutical in the upper half of its industry. The industry median Gross Margin % is 60.91. Sino Biopharmaceutical's value of 81.58% is 33.9% above this benchmark. Historically, Sino Biopharmaceutical's own Gross Margin % has ranged from 78.08 to 82.76 over the past decade. While the company's 10-year median is 80.03 vs. the industry median of 60.91, Sino Biopharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sino Biopharmaceutical's current Gross Margin % of 81.58% is 33.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sino Biopharmaceutical and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sino Biopharmaceutical's current Gross Margin % is 81.58%, which is near median its own 10-year median of 80.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.67, compared to a current price of $0.60 — trading 10.2% below its estimated fair value. The current Gross Margin % is 81.58%, which is near median its 10-year median of 80.03 and 33.9% above the Biotechnology industry median of 60.91. Sino Biopharmaceutical's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Gross Margin % is 81.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued.
The current stock price of $0.60 is trading 10.2% below its estimated GF Value™ of $0.67.
GuruFocus considers Sino Biopharmaceutical to be Modestly Undervalued.
Key valuation signals for SBMFF:
Gross Margin %: 81.58% (near median its 10-year median of 80.03)
GF Value™: $0.67 vs. price of $0.60 (10.2% below fair value)
Industry Position: 33.9% above the Biotechnology median (#188 of 736)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
62GF Score
Get the complete analysis for SBMFF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
